Medicinal and edible composition capable of improving immune function as well as preparation method and application of medicinal and edible composition
Through the medicinal and food homologous composition of Chinese medicine extracts such as Gastrodia elata, ginseng, American ginseng, Codonopsis pilosula, Astragalus, Ophiopogon japonicus, combined with the theory of traditional Chinese medicine compatibility, the problems of low absorption efficiency and poor safety of existing products have been solved, and the immune function has been significantly improved and stable quality effect.
Patent Information
- Application Number
- CN202411539471.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-31
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-10-31
AI Technical Summary
The existing products that improve immune function have problems such as low absorption efficiency, poor drug properties, poor safety, and difficult quality control. They lack the guidance of traditional traditional Chinese medicine theory and cannot effectively play the role of diet therapy.
The medicinal and food homologous composition of Chinese medicine extracts such as Gastrodia elata, ginseng, American ginseng, Codonopsis pilosula, Astragalus, Ophiopogon japonicus, etc. was designed through the theoretical design of traditional Chinese medicine compatibility, and the formulation was reasonably improved to significantly improve the immune function, and extracted through water extraction to avoid solvent loss and Exogenous impurities are introduced.
It provides safe, non-toxic, pleasant taste, stable and controllable medicinal and food products, significantly improves immune function, is suitable for long-term use, is applicable to a wide range of people, and has a significantly stronger effect than single medicinal materials.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] The invention relates to a medicine-food homologous composition capable of improving immune function, a preparation method and application thereof, and belongs to the field of medicines, foods or health foods. Background Art
[0002] Modern medical research has revealed that over 90% of human diseases are related to immune system disorders. A normal immune system can recognize and respond to all foreign antigens, while developing immune tolerance to its own cells and molecules. The immune system is responsible for the body's immune function. However, defects in any part of the immune system can weaken an individual's ability to defend against invading pathogens. Improving immunity is crucial to our health. The immune system is our body's defense system, helping us fight disease and infection. A strong immune system helps us fight viruses, bacteria, and other pathogens more easily, reducing the chance of illness. Furthermore, stronger immunity helps us recover faster and lessens the impact of illness. Improved immunity also helps us better cope with stress and environmental changes, maintaining good health and energy.
[0003] With the progress of society and fierce competition, the number of people with low immunity is increasing day by day, so people's demand for products that enhance immunity is increasing day by day. However, products that enhance immunity are no longer satisfied with biochemical products, and more and more people are favoring natural plant and traditional Chinese medicine extracts.
[0004] Traditional Chinese medicine, particularly herbal medicines, is gaining increasing attention worldwide for its safety and effectiveness, and represents a valuable resource for the development of products with both medicinal and edible properties. Currently, there are over 12,000 varieties of traditional Chinese medicine on the market, including over 11,000 herbal medicines, over 1,500 animal medicines, and over 80 mineral medicines. Drawing on the rich heritage of Chinese medicine spanning over 2,000 years of history, we are developing safer and more effective medicines, foods, and healthcare products by analyzing and extracting their active ingredients, then optimizing and improving them through combination therapy. Furthermore, by analyzing and mining the vast amount of existing TCM clinical data, we are uncovering clinical therapeutic clues, thereby developing new drugs, healthcare products, or therapies.
[0005] The material basis for the efficacy of traditional Chinese medicine (TCM) lies in its various chemical components. These components, when combined in a formula, produce complex physical and chemical reactions, which in turn influence the ultimate efficacy. Understanding TCM compatibility is crucial for accurately guiding TCM to achieve its intended efficacy and improving clinical efficacy. Guided by the fundamental theories of Traditional Chinese Medicine (TCM), TCM compatibility is based primarily on the theory of medicinal properties and TCM differentiation and treatment. It selectively applies herbs with properties, flavors, and functions that match the disease, syndrome, or symptom. Through compatibility, the goal is to enhance efficacy, improve treatment results, and mitigate toxic side effects.
[0006] Currently, there are numerous products designed to enhance immune function. However, existing products often have drawbacks, such as the numerous raw material sources, a wide variety of products, and varying quality, making it difficult for ordinary consumers to choose and discern. Processing significantly impacts the product's medicinal properties, resulting in poor overall absorption, making it inconvenient and hindering absorption. Existing processing techniques are crude, failing to effectively release multiple nutrients, and lacking the ability to complement or enhance nutritional benefits. Furthermore, some nutritional supplements are only suitable for specific populations. Formulated products fail to consider the compatibility between drugs, hindering disease treatment. Furthermore, these immune-enhancing products have varying tastes, and their formulations lack the guidance of traditional Chinese medicine theory, making them ineffective dietary therapies.
[0007] In view of this, developing an immune-enhancing product based on the wisdom of traditional Chinese medicine, which is safe, non-toxic, pleasant in taste, and suitable for long-term use, is not only an exploration of the integration of traditional medicine and modern technology, but also a major contribution to improving public health and promoting social welfare. Its economic value and social significance are self-evident. Summary of the Invention
[0008] The present invention provides a medicinal and edible composition for enhancing immune function, as well as its preparation method and application. The composition comprises ingredients such as Gastrodia elata extract, Panax ginseng extract, American ginseng extract, Codonopsis pilosula extract, Astragalus membranaceus extract, and Ophiopogon japonicus extract. The efficacy of the medicinal and edible composition for enhancing immunity was evaluated through animal experiments. The invention aims to address the problems of current immunity-enhancing products, such as low absorption efficiency, poor efficacy, poor safety, and difficult quality control, by providing a medicinal and edible product that effectively enhances immune function and is safe for the human body.
[0009] In order to achieve the above-mentioned purpose, the present invention adopts the following technical solutions:
[0010] The present invention provides a medicine-food composition capable of improving immunity, comprising Gastrodia elata extract, Ginseng extract, American ginseng extract, Codonopsis pilosula extract, Astragalus membranaceus extract and Ophiopogon japonicus extract.
[0011] Preferably, in the medicine-food composition, by mass percentage, the content of Gastrodia elata extract is not higher than 30%, the content of Panax ginseng extract is not higher than 25%, the content of American ginseng extract is not higher than 25%, the content of Codonopsis pilosula extract is not higher than 25%, the content of Astragalus membranaceus extract is not higher than 25%, and the content of Ophiopogon japonicus extract is not higher than 25%.
[0012] Preferably, the edible and medicinal composition comprises, by mass percentage, 5%-30% of Gastrodia elata extract, 5%-25% of Panax ginseng extract, 5%-25% of American ginseng extract, 5%-25% of Codonopsis pilosula extract, 5%-25% of Astragalus membranaceus extract, and 5%-25% of Radix Ophiopogonis extract. This edible and medicinal composition is formulated in accordance with the theory of Chinese medicine compatibility, has a reasonable formula, and can significantly enhance immune function through synergistic effects.
[0013] Preferably, the edible and medicinal composition comprises, by mass percentage, 10%-25% of Gastrodia elata extract, 10%-20% of Panax ginseng extract, 10%-20% of American ginseng extract, 10%-20% of Codonopsis pilosula extract, 10%-20% of Astragalus membranaceus extract, and 10%-20% of Ophiopogon japonicus extract.
[0014] More preferably, the medicine-food composition comprises, by mass percentage, 20% of Gastrodia elata extract, 13% of Ginseng extract, 12% of American ginseng extract, 14% of Codonopsis pilosula extract, 16% of Astragalus membranaceus extract, and 15% of Ophiopogon japonicus extract; or 15% of Gastrodia elata extract, 15% of Ginseng extract, 10% of American ginseng extract, 19% of Codonopsis pilosula extract, 16% of Astragalus membranaceus extract, and 14% of Ophiopogon japonicus extract; or 10% of Gastrodia elata extract, 19% of Ginseng extract, 14% of American ginseng extract, 11% of Codonopsis pilosula extract, 17% of Astragalus membranaceus extract, and 13% of Ophiopogon japonicus extract.
[0015] In some embodiments of the present invention, the extract is a solid powder obtained by taking the pharmacopoeial part of each medicinal material, crushing it, extracting it, separating it, and purifying it.
[0016] Preferably, the pharmacopoeial part of each medicinal material is extracted by water extraction, which avoids the loss of its active ingredients caused by other extraction methods such as solvent extraction, avoids the introduction of exogenous impurities, and can also concentrate the active ingredients.
[0017] The properties, flavors, meridians and effects of the drugs in the composition of the present invention are as follows:
[0018] Gastrodia elata: sweet, neutral, enters the liver meridian. Good at calming wind and relieving spasms, calming liver yang, treating liver yang and liver wind symptoms, regardless of cold, heat, deficiency or excess. It can dispel wind and dredge meridians, treat arthralgia, numbness of limbs and paralysis of hands and feet. Chemical composition studies have shown that Gastrodia elata contains phenols and their glycosides including gastrodin, p-hydroxybenzyl alcohol, vanillin, benzyl alcohol, etc.; polysaccharide organic acids and their esters, steroids and their glycosides, etc. Its main characteristic component is gastrodin. Modern pharmacological studies have shown that Gastrodia elata gastrodin and its metabolites can quickly pass through the blood-brain barrier, and have significant effects of helping sleep, anti-depression, anti-anxiety and improving learning ability. Gastrodia elata polysaccharides have the effect of enhancing the body's nonspecific immunity and cellular immunity.
[0019] Ginseng: Sweet, slightly bitter, and slightly warm, it enters the spleen, lung, heart, and kidney meridians. It is effective in replenishing vital energy and treating qi deficiency and impending collapse; it also tonifies spleen and lung qi to treat symptoms of spleen and lung qi deficiency; it also replenishes qi, promotes fluid production, calms the mind, and improves intelligence, treating thirst due to fluid deficiency, diabetes, restlessness, palpitations, and forgetfulness. Ginseng rhizomes contain various saponins and polysaccharides, the main characteristic components being ginsenoside Re, ginsenoside Rg1, and ginsenoside Rb1. It also contains amino acids, volatile oils, vitamins, and trace elements. Ginsenosides, polysaccharides, and oligopeptides significantly improve exercise-induced fatigue, postoperative fatigue, and chronic fatigue syndrome. Ginsenosides and ginseng polysaccharides exert anti-tumor, anti-inflammatory, and anti-aging effects by regulating immune cells and cytokines in immune organs.
[0020] American ginseng: Sweet, slightly bitter, and cooling, it enters the heart, lung, and kidney meridians. It is effective in tonifying qi and nourishing yin, clearing heat and promoting fluid production. It is primarily used to treat symptoms of qi and yin deficiency, or yin deficiency and fluid loss, particularly those with concurrent heat. The Chinese Pharmacopoeia stipulates that American ginseng must contain a minimum of 2.0% of ginsenoside Rg1, ginsenoside Re, and ginsenoside Rb1. It also contains polyacetylenes, flavonoids, lignans, organic acids, polysaccharides, sterols, volatile oils, peptides, amino acids, and proteins. American ginseng promotes serum protein synthesis and enhances immunity. As a qi-tonifying Chinese herb, American ginseng replenishes the body's deficiencies, strengthens function, and thereby improves disease resistance.
[0021] Codonopsis: Sweet and neutral. It enters the spleen and lung meridians. It is often used for mild cases of spleen and lung qi deficiency. It also promotes fluid production and nourishes blood, treating symptoms such as fluid and blood deficiency. The root of Codonopsis contains sterols, alkaloids, triterpenes, and volatile components, as well as a variety of trace elements, amino acids, and volatile oils. Modern pharmacological research indicates that Codonopsis has multiple pharmacological effects, including enhancing immunity, protecting the gastrointestinal mucosa, resisting ulcers, promoting hematopoiesis, regulating blood sugar, and delaying aging. It is also a health supplement and can be included in the diet.
[0022] Astragalus: Sweet and slightly warm, it enters the spleen and lung meridians. It tonifies middle Qi and elevates clear Yang, tonifies lung Qi, benefits the stomach, and strengthens the exterior. It treats spleen and lung Qi deficiency, sinking of middle Qi, Qi failure to retain blood, spontaneous sweating, and night sweats. It also promotes diuresis and reduces swelling, treating sores caused by Qi and blood deficiency that remain painful or protracted, as well as Qi deficiency edema and dysuria. Its chemical composition is complex, containing polysaccharides, various saponins, flavonoids, amino acids, linoleic acid, and alkaloids. Astragalus extract, extracted from the dried root of Astragalus, is primarily characterized by astragalus polysaccharides (APs).
[0023] Ophiopogon japonicus: sweet, slightly bitter, slightly cold. It enters the heart, lung, and stomach meridians. It nourishes yin, produces fluid, moistens the lungs, and benefits the stomach. It also clears the mind, relieves restlessness, and soothes the nerves. It also moistens the intestines and promotes bowel movements. It treats lung and stomach yin deficiency, restlessness, insomnia, and constipation caused by dry intestines. The Chinese Pharmacopoeia states that this product, calculated on a dry basis, contains 20% of the total Ophiopogon japonicus saponins, including ruscosaponin (C 27 H 42 O4) and must not be less than 0.12%. It also contains steroidal saponins, isoflavones, polysaccharides, volatile oils, and trace elements. The polysaccharides and flavonoids in Ophiopogon japonicus's bioactive components have demonstrated excellent efficacy in promoting cellular immunity in both clinical and laboratory studies, enhancing phagocyte activity and further resisting viral invasion.
[0024] Wherein, the preparation method of the Gastrodia elata extract is:
[0025] Preparation of Gastrodia elata extract: Gastrodia elata tubers are taken, crushed, extracted with water, filtered, and the residue is squeezed. The filtrate is combined, concentrated, dried, crushed, and sieved to obtain the Gastrodia elata extract.
[0026] Wherein, the preparation method of the ginseng extract is:
[0027] Preparation of ginseng extract: Take the root or rhizome of ginseng, crush it, add water to extract, filter it, squeeze the residue, combine the filtrate, concentrate it, dry it, crush it and sieve it to obtain the ginseng extract.
[0028] The preparation method of the American ginseng extract is as follows: the root of American ginseng is taken, crushed, extracted with water, filtered, the residue is squeezed, the filtrate is combined, concentrated, dried, crushed and sieved to obtain the American ginseng extract.
[0029] Wherein, the preparation method of the Codonopsis pilosula extract is:
[0030] Preparation of Codonopsis pilosula extract: Take the root of Codonopsis pilosula, crush it, add water to extract, filter it, squeeze the residue, combine the filtrate, concentrate it, dry it, crush it and sieve it to obtain the Codonopsis pilosula extract.
[0031] Wherein, the preparation method of the astragalus extract is:
[0032] Preparation of Astragalus Extract: Take the root of Astragalus, crush it, add water to extract, filter, squeeze the residue, combine the filtrate, concentrate, dry, crush and sieve to obtain the Astragalus Extract.
[0033] Wherein, the preparation method of the Ophiopogon japonicus extract is:
[0034] Preparation of Ophiopogon japonicus extract: Take the tuberous root of Ophiopogon japonicus, crush it, add water to extract, filter it, squeeze the residue, combine the filtrate, concentrate it, dry it, crush it and sieve it to obtain the Ophiopogon japonicus extract.
[0035] In some embodiments of the present invention, the edible and medicinal composition further comprises a sweetener.
[0036] In some preferred embodiments of the present invention, the mass percentage of the sweetener is 1-20%, more preferably 1-10%.
[0037] In some preferred embodiments of the present invention, the sweeteners include but are not limited to honey, sorbitol, maltitol, isomalt (also known as isomalt, palatinol), xylitol, lactitol, mannitol, erythritol, isomalt-oligosaccharides, stevioside, licorice, disodium glycyrrhizate, tripotassium glycyrrhizate, and trisodium glycyrrhizate.
[0038] In some embodiments of the present invention, the medicine-food composition further includes a pharmaceutically acceptable excipient.
[0039] Preferably, the auxiliary materials include at least one of fillers, lubricants, dispersants, wetting agents, binders, disintegrants, antioxidants, and preservatives.
[0040] The fillers include but are not limited to maltodextrin, fructooligosaccharides, galacto-oligosaccharides, resistant dextrin, inulin, mannitol, and cellulose.
[0041] The lubricant includes but is not limited to micro powder silica gel, silicon dioxide, magnesium stearate, and sodium stearyl fumarate.
[0042] The wetting agent generally includes purified water or ethanol solutions in different proportions.
[0043] The disintegrant generally includes sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone and the like.
[0044] In some embodiments of the present invention, the medicine-food composition can be prepared into any one of a decoction, tablet, powder, powder, pill, granule, oral solution, capsule or paste dosage form. The above dosage forms can be prepared by conventional processes in the art and will not be described in detail here.
[0045] The present invention provides use of the composition in preparing a product for improving immunity.
[0046] The products described in the present invention include medicines, foods and health products.
[0047] Beneficial effects:
[0048] The medicine-food combination provided by the present invention combines the immune view of traditional Chinese medicine, is based on the holistic concept of traditional Chinese medicine, and combines the effective ingredients in modern medicine that can enhance immune molecules and cytokines, thereby achieving significant improvement in immunity and effectively enhancing immune function.
[0049] The medicine-food composition according to the embodiment of the present invention has at least the following beneficial effects: the medicine-food composition provided by the present invention, the formula contains the medicine-food raw materials Gastrodia elata extract, ginseng extract, American ginseng extract, Codonopsis pilosula extract, Astragalus extract, Ophiopogon japonicus extract, etc., the formula naturally carries the known functions of the above-mentioned traditional Chinese medicines themselves, and the effect is predictable. The present invention follows the theory of Chinese medicine compatibility to design the formula, and the compatibility is reasonable, so that the composition has the effects of replenishing qi and raising yang, benefiting the defense and strengthening the exterior, restoring the pulse and strengthening the body, strengthening the spleen and benefiting the lungs, and strengthening the body's resistance and eliminating evil, and has significant therapeutic effects. The composition has no adverse effects on the weight gain of mice, and modern pharmacological models have confirmed that it can significantly improve the immunity of mice with high immunodeficiency model, which is more significant than the effect of single medicinal materials, meets the evaluation standards for health foods that enhance immunity, and has the function of synergistically enhancing immunity. Moreover, the composition of the present invention is prepared from natural Chinese herbal medicine extracts that are both medicinal and edible, which is safe, has no toxic side effects, is harmless to the body, and can nourish the body; the quality is stable and controllable; there is no special odor, the taste is good, and it can be taken directly; it is applicable to a wide range of people, suitable for consumption by middle-aged and elderly people, and can be taken for a long time without adverse reactions, and has high practical application value. DETAILED DESCRIPTION
[0050] The technical solution of the present invention is further described below by way of specific embodiments. It should be understood by those skilled in the art that the embodiments are merely to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0051] The processes, conditions, reagents, and experimental methods used in the present invention are, except for those specifically mentioned below, common knowledge and general general knowledge in the art and are not particularly limited by the present invention. Experimental methods in the examples where specific conditions are not specified are generally performed under conventional conditions or as recommended by the manufacturer.
[0052] Unless otherwise specified, all technical and scientific terms used in this specification have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. However, in the event of any conflict, the present specification including the definitions shall prevail.
[0053] Example 1 Preparation of a medicinal and edible extract for improving immunity
[0054] (1) Preparation method of Gastrodia elata extract:
[0055] The raw material of Gastrodia elata was crushed and passed through a 20-mesh sieve to remove fine powder and impurities to obtain a coarse powder of the medicinal material; the coarse powder of the medicinal material was poured into an extraction tank, and water 10 to 12 times the weight of the medicinal material was added and soaked for 50 minutes; the soaked medicinal material was heated and boiled for 2 hours, filtered, and the supernatant was collected for later use; the extracted and filtered medicinal residue was again added with 8 to 10 times the weight of water, heated and boiled for 2 hours, filtered, and the supernatant was collected; the supernatants of the two filtrations were combined, transferred to an evaporation tank, and heated and concentrated to a specific gravity of 1.08 to 1.15 g / cm 3 Filter and remove impurities, collect the filtrate; the filtrate is then concentrated to a specific gravity of 1.20~1.30g / cm 3 extract; the extract is transferred to a tray, evenly spread, and placed in a freezer for quick freezing; the frozen extract is transferred to a freezing chamber for programmed freeze drying, freeze drying until the moisture content is less than 5.0%, obtaining a dry product, crushing and sieving, and obtaining the Gastrodia elata extract.
[0056] (2) The preparation method and process of ginseng extract, American ginseng extract, Codonopsis pilosula extract, Astragalus root extract and Ophiopogon japonicus extract are as follows: (1) Preparation method of Gastrodia elata extract
[0057] Example 2 Preparation of edible and medicinal composition granules for improving immunity
[0058] The components in this embodiment are composed of the following mass percentage components: 20% of Gastrodia elata extract, 13% of ginseng extract, 12% of American ginseng extract, 14% of Codonopsis pilosula extract, 16% of Astragalus extract, 15% of Ophiopogon japonicus extract solid powder, and 10% of stevia.
[0059] Preparation method:
[0060] Grind each of the extract powders and stevia and pass through a 60-mesh sieve to remove coarse particles, and mix well;
[0061] The extract mixture was granulated with 75% by weight of food-grade ethanol and sieved through 20 mesh;
[0062] Dry at 50-55°C, determine the moisture content according to the method of the Pharmacopoeia of the People's Republic of China, Part II, 2020 edition, and control the moisture content to 5%;
[0063] The dried granules were sieved through a 20-mesh sieve, and 0.5% (by weight of granules) of micro-powdered silica gel was added as an auxiliary material. The mixture was evenly mixed and bagged to obtain granules.
[0064] Example 3 Preparation of capsules of a medicinal and edible composition for improving immunity
[0065] The components in this embodiment are composed of the following components in mass percentage: 15% of Gastrodia elata extract, 15% of ginseng extract, 10% of American ginseng extract, 19% of Codonopsis pilosula extract, 16% of Astragalus membranaceus extract, 14% of Ophiopogon japonicus extract solid powder, and 11% of maltodextrin.
[0066] Preparation method:
[0067] Each of the above extract powders and maltodextrin was crushed and passed through a 60-mesh sieve to remove coarse particles, and then mixed evenly;
[0068] The extract mixture was mixed with 80% by weight of food-grade ethanol, granulated, and sieved through 20 mesh;
[0069] Put it into a cold oven, turn on the air blower, and when the surface of the particles turns white, turn them over with a shovel, then heat to 30-35℃, turn them over again after 20-60 minutes, and continue drying;
[0070] When the particles are loosely dispersed, heat them to 50-55°C and dry them. Determine their moisture content according to the method of the Pharmacopoeia of the People's Republic of China, Part II, 2020 edition, and control their moisture content to 5% by weight.
[0071] The dried particles were cooled, and 0.5% (by particle weight) of silicon dioxide was added and mixed evenly, and then filled into 0# capsules to obtain capsules.
[0072] Example 4 Preparation of Food and Medicine Composition Tablets for Improving Immunity
[0073] The components in this embodiment are composed of the following components in mass percentage: 10% of Gastrodia elata extract, 19% of Ginseng extract, 14% of American ginseng extract, 11% of Codonopsis pilosula extract, 17% of Astragalus extract, 13% of Ophiopogon japonicus extract\solid powder, 10% maltodextrin, and 6% sodium carboxymethyl starch.
[0074] Preparation method:
[0075] Each of the extract powders and maltodextrin was crushed and passed through a 60-mesh sieve to remove coarse particles, mixed evenly, and then sodium carboxymethyl starch was added and mixed evenly;
[0076] The extract mixture was mixed with 85% by weight of food-grade ethanol, granulated, and sieved through 20 mesh;
[0077] The granules were dried at 50-55°C, and the moisture content was determined according to the method of the Pharmacopoeia of the People's Republic of China, Part II, 2020 edition, and the moisture content was controlled to be 6% by weight;
[0078] The dried granules were sieved through a 20-mesh sieve, and 0.5% (by weight of granules) of micro-powdered silica gel and 0.5% (by weight of granules) of magnesium stearate were added and mixed evenly, and then tabletted to obtain tablets.
[0079] Example 5 Evaluation of the immunomodulatory function of the composition in an immunocompromised mouse model
[0080] In this example, the immunomodulatory effects of the composition of the present invention and a single-component drug as a comparative example on immunocompromised mice were tested.
[0081] 1. Experimental methods:
[0082] 1.1 Animal grouping
[0083] 120 male mice were acclimated for one week before the experiment to acclimate to the environment. Mice were randomly divided into 10 groups: a normal control group, a model control group, a Gastrodia elata group, a Panax ginseng group, an American ginseng group, a Codonopsis pilosula group, an Astragalus membranaceus group, an Ophiopogon japonicus group, a group treated with the composition of Example 2, a group treated with the composition of Example 3, a group treated with the composition of Example 4, and a positive control group (Zidaxin).
[0084] 1.2 Immunosuppressed mouse model establishment and drug administration in each group
[0085] Normal control group: The mice were raised in groups and isolated from other groups, and were given normal feed and drinking water as needed.
[0086] Model control group: Cyclophosphamide was intraperitoneally injected at a dose of 80 mg / kg on days 7, 8, and 9 of the experiment.
[0087] Intervention group: The feeding environment and modeling method were the same as those of the model group. During the 14 days of the experiment, the rats were gavaged daily at the same dose of Gastrodia elata extract, Ginseng extract, American ginseng extract, Codonopsis pilosula extract, Astragalus extract, Ophiopogon japonicus extract, the composition group of Example 2, the composition group of Example 3, and the composition group of Example 4.
[0088] Zidaxin group: The feeding environment and modeling method were the same as those of the model group, and the drug was administered subcutaneously at a dose of 0.2 mg / kg within 14 days of the experiment.
[0089] 1.3 Detection indicators
[0090] 1.3.1 Organ Index
[0091] The thymus and spleen are major immune organs in the body. Changes in their mass can reflect the stimulatory effects of the test drug on the immune system. Therefore, the thymus and spleen indices are considered important indicators of immune function. At the end of the experiment, mice were sacrificed, and the thymus and spleen were removed. Blood was blotted off with filter paper, and the thymus and spleen indices were weighed to calculate the thymus and spleen indices. Spleen index = spleen weight (mg) / body weight (g); thymus index = thymus weight (mg) / body weight (g).
[0092] 1.3.2 Routine determination of mouse peripheral blood
[0093] Routine blood test data can directly reflect the effect of the composition on cells in the peripheral blood of immunocompromised mice. White blood cells are one of the main executors of the human immune function, and the level of white blood cells in the blood reflects the strength of the immune function to a certain extent. After cyclophosphamide modeling, there is a significant effect on the white blood cell index parameters in the mouse blood. Whole blood is collected from the mouse eyeball and placed in an anticoagulant tube. The white blood cell count (WBC), neutrophil count (NEUT), lymphocyte count (LYMPH), monocyte count (MONO) and other indicators in the mouse blood are detected using a fully automatic cell analyzer.
[0094] 2. Experimental results
[0095] 2.1 Effects on organ indices of experimental animals
[0096] After 14 days of administration, the thymus index and spleen index of the model group mice were significantly decreased compared with the blank group, indicating that cyclophosphamide can induce immunosuppression in mice. Compared with the model group, the thymus index and spleen index of the mice in the Gastrodia elata group, the ginseng group, the American ginseng group, the Codonopsis pilosula group, the Astragalus group, the Ophiopogon japonicus group, the combination group, and the Zidaxin group were significantly increased, indicating that the single component group, the combination group, and Zidaxin have a significant improvement effect on the spleen and thymus damage of mice caused by cyclophosphamide. In addition, compared with the Gastrodia elata group, the ginseng group, the American ginseng group, the Codonopsis pilosula group, the Astragalus group, and the Ophiopogon japonicus group, the thymus index and spleen index of the mice in the combination group were statistically different, suggesting that the combination group has an synergistic or synergistic effect. The results are shown in Table 1.
[0097] Table 1
[0098] Group Thymus index (mg / g) Spleen index (mg / g) Blank control group 1.88±0.21 6.37±0.69 Model control group 0.65±0.12# 2.38±0.58# Gastrodia elata group 0.81±0.22*^ 3.49±0.52*^ Ginseng group 1.14±0.34*^ 4.17±0.41*^ American ginseng group 1.18±0.26*^ 4.41±0.54*^ Codonopsis group 0.91±0.32*^ 3.67±0.32*^ Astragalus group 0.89±0.32*^ 3.47±0.31*^ Ophiopogon japonicus group 0.91±0.22*^ 3.98±0.44*^ Example 2 Composition Group 1.94±0.29* 6.19±0.55* Example 3 Composition Group 1.73±0.32* 5.67±0.46* Example 4 Composition 1.86±0.18* 5.87±0.39* Positive control group 1.67±0.35* 5.68±0.43*
[0099] Note: Compared with the blank control group, #P < 0.05; compared with the model control group, *P < 0.05; compared with the combination group, ^P < 0.05.
[0100] 2.2 Effects on peripheral blood routine of experimental animals
[0101] Compared with the blank control group, the levels of white blood cells (WBC), lymphocytes (LYMPH), neutrophils (NEUT), and monocytes (MONO) in the peripheral blood of mice in the model group were significantly reduced. Compared with the model group, the Gastrodia elata group, the Panax ginseng group, the American ginseng group, the Codonopsis pilosula group, the Astragalus group, the Radix Ophiopogonis group, the combination, and Ridaxin were able to significantly increase the levels of white blood cells (WBC), lymphocytes (LYMPH), neutrophils (NEUT), and monocytes (MONO) in the blood routine of immunocompromised mice. In addition, compared with the Gastrodia elata group, the Panax ginseng group, the American ginseng group, the Codonopsis pilosula group, the Astragalus group, and the Radix Ophiopogonis group, the levels of white blood cells (WBC), lymphocytes (LYMPH), neutrophils (NEUT), and monocytes (MONO) in the combination group were statistically different, suggesting that the combination group has an enhancing or synergistic effect. The results are shown in Table 2.
[0102] Table 2
[0103]
[0104] Note: Compared with the blank control group, #P < 0.05; compared with the model control group, *P < 0.05; compared with the combination group, ^P < 0.05.
[0105] 3. Experimental Conclusions and Discussion
[0106] After 14 days of administration, the combination significantly increased the spleen and thymus indices of immunocompromised mice, as well as the number of white blood cells, lymphocytes, neutrophils, and monocytes in the peripheral blood of immunocompromised mice, demonstrating that the combination can ameliorate cyclophosphamide-induced spleen and thymus damage in immunocompromised mice. Furthermore, the combination's effect was significantly greater than that of each individual group, suggesting a synergistic or potent effect.
[0107] Example 6 Evaluation of the Effect of the Composition on the Immune Function of Mice
[0108] In this example, the effects of the composition of the present invention and a single-component drug as a comparative example on the immune function of mice were tested from four aspects: cellular immunity, humoral immunity, monocyte-macrophage function, and natural killer cell (NK) activity.
[0109] 1. Experimental methods:
[0110] 1.1 Animal grouping
[0111] 330 SPF (specific pathogen free) Kunming healthy male mice were selected and randomly divided into three groups according to body weight, with 110 mice in each group. The three groups were immune group 1, immune group 2, and immune group 3.
[0112] 1.2 Experimental samples
[0113] Sheep red blood cells (SRBC), Hank's solution (balanced salt solution) (pH 7.2-7.4), RPMI1640 culture medium, calf serum, penicillin-streptomycin, concanavalin A (ConA), MTT (methylthiazolium tetrazolium), complement (guinea pig serum), SA buffer, India ink, Dulbecco's reagent, YAC-1 cells, etc.
[0114] 1.3 Modeling method
[0115] The mice were divided into three groups: group 1 was tested for delayed-type hypersensitivity (DTH) and antibody-producing cell counts; group 2 was tested for ConA-induced mouse lymphocyte transformation and NK cell activity; and group 3 was tested for carbon clearance. Adaptive feeding was continued for three days.
[0116] 110 mice in each group were randomly divided into 11 groups: blank control, model control, Gastrodia elata, Ginseng, American ginseng, Codonopsis pilosula, Astragalus membranaceus, Ophiopogon japonicus, the combination group of Example 2, the combination group of Example 3, and the combination group of Example 4. The blank and model control groups were given 1 mL / 10 g of distilled water; the intervention groups were given the same volume of Gastrodia elata, Ginseng, American ginseng, Codonopsis pilosula, Astragalus membranaceus, Ophiopogon japonicus, and the combination. This was administered orally for 15 consecutive days. Ten days before the end of the experiment, mice in the intervention and model groups were sensitized with 80 mg / kg of cyclophosphamide intraperitoneally for 3 consecutive days to create immunocompromised mice. The blank group was given an equal volume of normal saline (0.1 mL / 10 g) intraperitoneally.
[0117] 1.4 Detection indicators
[0118] 1.4.1 Cellular immune function
[0119] Delayed-type hypersensitivity (DTH) (plantar thickening method): Mice were sensitized by intraperitoneal injection of 2% packed SRBC (0.2 ml / mouse) for 4 days, and the thickness of the left hind paw was measured. Then 20% (v / v) SRBC (20 μL / mouse) was injected subcutaneously at the measurement site. The thickness of the left hind paw was measured 24 hours after injection. The same site was measured three times and the average value was taken. The difference in the thickness of the anterior and hind paws (plantar swelling) was used to express the degree of DTH.
[0120] ConA-induced mouse lymphocyte transformation test (MTT method): Aseptically remove the spleen and grind it with forceps in a sterile Hank's solution dish to prepare a cell suspension. Filter through a 200-mesh sieve and wash twice with Hank's solution, centrifuging each time for 10 minutes (1000 rpm). Then, take the precipitate and suspend it in 1 mL of complete culture medium. Stain with trypan blue and count the cells (should be above 95%). Adjust the cell concentration to 3×10 6The cell suspension was then divided into two wells of a 24-well culture plate, 1 mL per well. 75 μL of ConA solution was added to one well, while the other well served as a control. The cells were incubated at 37°C in a 5% CO2 incubator for 72 hours. Four hours before the end of the incubation period, 0.7 mL of supernatant was gently aspirated from each well, and 0.7 mL of RPMI-1640 culture medium without calf serum was added. MTT (5 mg / mL) was also added at 50 μL / well and the cells were incubated for another 4 hours. After the incubation period, 1 mL of acidic isopropanol was added to each well to completely dissolve the purple product. The cells were then aliquoted into a 96-well culture plate, with triplicate wells per well. The optical density was measured at 570 nm using a microplate reader. The proliferation capacity of lymphocytes was determined by subtracting the A value of the well without ConA from the A value of the well with ConA.
[0121] 1.4.2 Humoral immune function
[0122] Antibody-producing cell detection (Jerne modified slide method): Each mouse was intraperitoneally injected with 0.2 mL of 2% packed SRBC. Five days after immunization, the mice were killed by cervical dislocation. The spleens were removed and placed in a dish containing Hank's solution. The spleens were ground to prepare a cell suspension, filtered through a 200-mesh sieve, centrifuged (1000 rpm) for 10 min, and washed twice with Hank's solution. Finally, the cells were suspended in 5 mL of RPMI1640 culture medium and counted by trypan blue staining (should be above 95%). The cell concentration was adjusted to 5 × 10 6 A spleen cell suspension was prepared at a concentration of 1% agarose / mL. A 1% aqueous solution was prepared by boiling agarose in a water bath for 30 minutes. The solution was then mixed with an equal volume of double-strength Hanks' solution and dispensed into small test tubes, 0.5 mL per tube. 50 μL of 10% packed SRBC (prepared in SA buffer) was then added to the tubes. Two replicates of 20 μL of the spleen cell suspension were prepared and mixed quickly. The suspension was then poured onto a thin agarose layer slide. After the agar solidified, the slide was placed horizontally on a slide rack and incubated in a CO2 incubator for 1.5 hours. Complement was then added to the grooves of the slide rack and incubated for another 1.5 hours. The number of hemolytic plaques was then counted. To prepare the complement, guinea pig blood was collected, serum was separated (pooled sera from at least five guinea pigs), and 1 mL of packed SRBC was added to 5 mL of guinea pig serum. The solution was refrigerated at 4°C for 30 minutes with frequent shaking. The supernatant was centrifuged, aliquoted, and stored at -70°C. The solution was diluted 1:15 with SA buffer for use.
[0123] 1.4.3 Monocyte-macrophage phagocytic function
[0124] The carbon clearance test was used to assess the phagocytic function of mouse monocytes and giant cells. 25% India ink was injected into the tail vein of mice at a dose of 0.1 mL / 10 g. Five and 20 minutes after injection, 25 μL of blood was collected from the orbital venous plexus of the mice and dissolved in 2 mL of 0.1% Na₂CO₃ solution, shaken evenly. 0.1% Na₂CO₃ was used as a blank control. The absorbance was measured at 600 nm using a spectrophotometer. The mice were dissected and the liver and spleen were weighed. The clearance index K and the corrected clearance index α were calculated. Here, K = (1 g A₁ - 1 g A₂) / (t₂ - t₁); α = K₁ / 3 body weight / (liver weight + spleen weight). A₁ and A₂ represent the absorbance values measured at two successive times, and t₂ - t₁ represents the time interval between the two blood draws.
[0125] 1.4.4 NK cell activity assay
[0126] NK cell activity was detected by lactate dehydrogenase (LDH) assay. YAC-1 cells were subcultured 24 h before the experiment and the cell concentration was adjusted to 4 × 10 5 After administration, the spleen was removed aseptically and placed in a small dish containing an appropriate amount of sterile Hank's solution. The spleen was gently ground with forceps to prepare a single-cell suspension. Filtered through a 200-mesh sieve, 0.5 mL of sterile water was added for 20 seconds to lyse the red blood cells, and the cell concentration was adjusted to 2 × 10 cells / mL using RPMI1640 complete culture medium. 7 100 μL each of YAC-1 cells and spleen cells was added to a 96-well culture plate. 100 μL each of target cells and culture medium was added to the wells for natural target cell release, and 100 μL each of target cells and 2.5% Triton was added to the wells for maximum target cell release. Three replicates were set up for each well and incubated in a 37°C, 5% CO2 incubator for 4 h. The 96-well culture plate was then centrifuged at 1500 rpm for 5 min. 100 μL of the supernatant from each well was aspirated and placed in a flat-bottomed 96-well culture plate. 100 μL of LDH substrate solution was added and the reaction was continued for 3 min. 30 μL of 1 mol / L hydrochloric acid solution was added to each well, and the A value was measured at 490 nm using a microplate reader.
[0127] NK cell activity (%) = (reaction A value - natural release pore A value) / (maximum release pore A value - natural release pore A value) × 100%.
[0128] 2. Experimental results
[0129] Excel and SPSS 19.0 software were used for data transformation and statistical analysis. After the homogeneity of variance test was passed, single-factor multiple comparison statistical analysis was performed.
[0130] 2.1 Cellular immune function
[0131] In a delayed-type hypersensitivity test in mice, the model group showed a significant reduction in delayed-type hypersensitivity compared to the blank control group (P < 0.01). Compared to the model group, the intervention group significantly increased the intensity of delayed-type hypersensitivity reactions in mice (P < 0.01), demonstrating that the composition of the present invention can enhance delayed-type hypersensitivity reactions in mice. Furthermore, the combination showed a significantly stronger effect than either of the individual control groups, suggesting a synergistic or synergistic effect. The results are shown in Table 3.
[0132] In an experiment on ConA-induced mouse splenic lymphocyte transformation, the A value difference in the intervention group was significantly higher than that in the model control group, indicating that the intervention group enhanced the ability of mouse splenic lymphocyte transformation. Furthermore, the combination was significantly more effective than either of the individual groups, suggesting a synergistic or potentiating effect. The results are shown in Table 3.
[0133] Table 3
[0134] Group Toe thickness difference (mm) A value difference Blank control group 0.78±0.31 0.468±0.083 Model control group 0.25±0.22# 0.228±0.059# Gastrodia elata group 0.43±0.13*^ 0.339±0.032*^ Ginseng group 0.54±0.32*^ 0.407±0.051*^ American ginseng group 0.58±0.24*^ 0.409±0.064*^ Codonopsis group 0.45±0.16*^ 0.352±0.024*^ Astragalus group 0.59±0.24*^ 0.418±0.032*^ Ophiopogon japonicus group 0.42±0.15*^ 0.361±0.026*^ Example 2 Composition Group 0.78±0.26* 0.481±0.019* Example 3 Composition Group 0.69±0.19* 0.446±0.012* Example 4 Composition 0.72±0.21* 0.469±0.011*
[0135] Note: Compared with the blank control group, #P < 0.05; compared with the model control group, *P < 0.05; compared with the combination group, ^P < 0.05.
[0136] 2.2 Humoral immune function
[0137] In the mouse antibody-producing cell experiment, the number of hemolytic plaques in the intervention group was significantly different from that in the model control group (P < 0.05), indicating that the combination increased the number of antibody-producing cells in mice and enhanced their humoral immunity. Furthermore, the combination was significantly more effective than either of the individual groups, suggesting a synergistic or potentiating effect. The results are shown in Table 4.
[0138] Table 4
[0139] Group <![CDATA[Number of hemolytic plaques (10 3 splenocytes)]]> Blank control group 23.86±6.79 Model control group 10.37±5.47# Gastrodia elata group 15.43±7.16*^ Ginseng group 18.35±6.28*^ American ginseng group 19.35±6.47*^ Codonopsis group 16.57±5.23*^ Astragalus group 19.79±4.59*^ Ophiopogon japonicus group 15.78±4.16*^ Example 2 Composition Group 24.38±5.98* Example 3 Composition Group 21.46±4.79* Example 4 Composition 22.67±3.99*
[0140] Note: Compared with the blank control group, #P < 0.05; compared with the model control group, *P < 0.05; compared with the combination group, ^P < 0.05.
[0141] 2.3 Monocyte-macrophage phagocytic function
[0142] In a mouse carbon clearance experiment, carbon clearance was significantly reduced in immunocompromised mice in the model control group compared with the blank control group (P < 0.01). However, carbon clearance was significantly improved in the intervention group compared with the model control group (P < 0.05), indicating enhanced phagocytosis of mouse monocytes and macrophages. Furthermore, the combination was significantly more effective than either of the individual groups, suggesting a synergistic or potentiating effect. The results are shown in Table 5.
[0143] Table 5
[0144] Group Phagocytic index (α) Blank control group 4.46±0.58 Model control group 2.28±0.49# Gastrodia elata group 3.25±0.45*^ Ginseng group 3.66±0.56*^ American ginseng group 3.77±0.52*^ Codonopsis group 3.16±0.56*^ Astragalus group 3.84±0.51*^ Ophiopogon japonicus group 3.19±0.47*^ Example 2 Composition Group 4.59±0.47* Example 3 Composition Group 4.23±0.35* Example 4 Composition 4.38±0.37*
[0145] Note: Compared with the blank control group, #P < 0.05; compared with the model control group, *P < 0.05; compared with the combination group, ^P < 0.05.
[0146] 2.4 NK cell activity assay
[0147] In the lactate dehydrogenase (LDH) assay to measure NK cell activity, the model control group showed significantly lower NK cell activity compared to the blank control group (P < 0.01). Compared to the model control group, the intervention group showed significantly higher NK cell activity (P < 0.05), indicating that the combination enhanced NK cell activity in mice. Furthermore, the combination was significantly more effective than either of the individual groups, suggesting a synergistic or synergistic effect. The results are shown in Table 6.
[0148] Table 6
[0149] Group NK cell activity (%) Blank control group 27.76±4.91 Model control group 9.68±2.32# Gastrodia elata group 15.57±4.37*^ Ginseng group 22.59±3.19*^ American ginseng group 23.49±3.03*^ Codonopsis group 15.57±4.26*^ Astragalus group 22.59±3.19*^ Ophiopogon japonicus group 14.38±4.15*^ Example 2 Composition Group 28.89±2.87* Example 3 Composition Group 25.96±3.15* Example 4 Composition 26.99±2.98*
[0150] Note: Compared with the blank control group, #P < 0.05; compared with the model control group, *P < 0.05; compared with the combination group, ^P < 0.05.
[0151] The composition of the present invention can significantly increase the intensity of delayed-type hypersensitivity reactions in mice; enhance the transformation and proliferation of mouse splenic lymphocytes induced by concanavalin A (ConA), thereby enhancing cellular immunity; increase the number of antibody-producing cells in mice, thereby enhancing humoral immunity; and enhance the phagocytic function of mouse monocytes and macrophages and the activity of mouse NK cells. Furthermore, the combined effect is significantly stronger than that of each individual group, indicating that the combined group has a synergistic or synergistic effect. This demonstrates that the composition of the present invention has a certain effect in enhancing immunity.
[0152] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be determined by the appended claims.
[0153] The applicant declares that the present invention uses the above-mentioned embodiments to illustrate the medicinal and edible composition, its preparation method, and its application, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvements to the present invention, equivalent replacements of various raw materials in the product of the present invention, addition of auxiliary ingredients, and selection of specific methods, etc., all fall within the scope of protection and disclosure of the present invention.
[0154] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the scope of protection of the present invention.
[0155] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any appropriate manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A medicine-food composition having the function of improving immunity, characterized in that: The medicine-food composition comprises gastrodia elata extract, ginseng extract, American ginseng extract, codonopsis pilosula extract, astragalus extract and ophiopogon japonicus extract.
2. The medicine-food composition for improving immunity according to claim 1, characterized in that: In the edible-medicinal composition, by weight percentage, the content of Gastrodia elata extract is not higher than 30%, the content of ginseng extract is not higher than 25%, the content of American ginseng extract is not higher than 25%, the content of Codonopsis pilosula extract is not higher than 25%, the content of Astragalus membranaceus extract is not higher than 25%, and the content of Ophiopogon japonicus extract is not higher than 25%.
3. The medicine-food composition for improving immunity according to claim 2, characterized in that: The edible and medicinal composition comprises, by mass percentage, 5%-30% of Gastrodia elata extract, 5%-25% of Ginseng ginseng extract, 5%-25% of American ginseng extract, 5%-25% of Codonopsis pilosula extract, 5%-25% of Astragalus membranaceus extract, and 5%-25% of Ophiopogon japonicus extract.
4. The medicine-food composition for improving immunity according to claim 3, characterized in that: The medicine-food composition comprises, by mass percentage, 10%-25% of Gastrodia elata extract, 10%-20% of Ginseng extract, 10%-20% of American ginseng extract, 10%-20% of Codonopsis pilosula extract, 10%-20% of Astragalus extract, and 10%-20% of Ophiopogon japonicus extract.
5. The medicine-food composition for improving immunity according to claim 1, characterized in that: The medicine-food composition comprises, by mass percentage, 20% of Gastrodia elata extract, 13% of Ginseng extract, 12% of American ginseng extract, 14% of Codonopsis pilosula extract, 16% of Astragalus membranaceus extract, and 15% of Ophiopogon japonicus extract; or 15% of Gastrodia elata extract, 15% of Ginseng extract, 10% of American ginseng extract, 19% of Codonopsis pilosula extract, 16% of Astragalus membranaceus extract, and 14% of Ophiopogon japonicus extract; or 10% of Gastrodia elata extract, 19% of Ginseng extract, 14% of American ginseng extract, 11% of Codonopsis pilosula extract, 17% of Astragalus membranaceus extract, and 13% of Ophiopogon japonicus extract.
6. The edible-medicinal composition according to any one of claims 1 to 5, characterized in that: Each of the extracts is prepared from the pharmacopoeial part of the medicinal material, which is crushed, extracted, separated and purified to obtain a solid powder; the extraction methods are all water extraction methods.
7. The edible-medicinal composition according to any one of claims 1 to 5, characterized in that: The medicine-food composition also includes a sweetener; The mass percentage of the sweetener is 1-20%; The sweetener is selected from one or more of sorbitol, maltitol, isomalt, xylitol, lactitol, mannitol, erythritol, isomalt-oligosaccharide, stevioside, licorice, disodium glycyrrhizinate, tripotassium glycyrrhizinate and trisodium glycyrrhizinate.
8. A method for preparing the medicine-food composition according to any one of claims 1 to 5, characterized in that: Gastrodia elata extract, ginseng extract, American ginseng extract, Codonopsis pilosula extract, Astragalus membranaceus extract and Ophiopogon japonicus extract are weighed according to weight ratio, sieved, added with conventional auxiliary materials and mixed evenly to obtain a compatible composition.
9. Use of the medicine-food composition according to any one of claims 1 to 5 in the preparation of medicines, foods or health products for improving immunity.
10. A Chinese medicine preparation for improving immunity, characterized in that: The traditional Chinese medicine preparation comprises the medicine-food composition as described in any one of claims 1 to 5.
11. The Chinese medicine preparation according to claim 10, characterized in that: The dosage form of the Chinese medicine preparation is selected from decoction, tablet, powder, powder, pill, granule, oral liquid, capsule or paste dosage form.
12. A health product that helps improve immunity, characterized in that: The health product comprises the medicine-food composition as described in any one of claims 1 to 5.
Citation Information
Patent Citations
Tonic grape wine
CN102911831A
Health-care food capable of improving immunity and reducing blood fat and preparation method thereof
CN103584091A
Composition for enhancing immunity and relieving weariness and preparation method of composition
CN108095078A
Traditional Chinese medicine composition for improving immunity and preparation method thereof
CN112220887A
